Key result
Selective β3 adrenergic receptor antagonism with L-748,337 attenuated dobutamine-induced progressive impairment in cardiac efficiency while preserving inotropy in an anesthetized pig model.
Why the study?
Excessive myocardial oxygen consumption limits catecholamine use, and it was hypothesized that dobutamine-induced increases in MVO2 relate to myocardial metabolism and can be prevented by selective beta 3 adrenergic receptor antagonism.
Does L-748,337 attenuate dobutamine-induced cardiac inefficiency in an open-chest pig model?
Does L-748,337 attenuate dobutamine-induced cardiac inefficiency in an open-chest pig model?
Selective β3 adrenergic receptor antagonism with L-748,337 attenuates dobutamine-induced cardiac inefficiency without compromising inotropy in a pig model.
Answers are grounded in this paper and cite their sources.
β3 antagonism may mitigate catecholamine-induced inefficiency without losing inotropy in pigs; hypothesis-generating for human HF trials.
Excessive myocardial oxygen consumption (MVO 2 ) is considered a limitation for catecholamines, termed oxygen cost of contractility. We hypothesize that increased MVO 2 induced by dobutamine is not directly related to contractility but linked to intermediary myocardial metabolism. Furthermore, we hypothesize that selective β 3 adrenergic receptor (β 3 AR) antagonism using L-748,337 prevents this. In an open-chest pig model, using general anesthesia, we assessed cardiac energetics, hemodynamics and arterial metabolic substrate levels at baseline, ½ hour and 6 hours after onset of drug infusion. Cardiac efficiency was assessed by relating MVO 2 to left ventricular work (PVA; pressure–volume area). Three groups received dobutamine (5 μg/kg/min), dobutamine + L-748,337 (bolus 50 μg/kg), or saline for time-matched controls. Cardiac efficiency was impaired over time with dobutamine infusion, displayed by persistently increased unloaded MVO 2 from ½ hour and 47% increase in the slope of the PVA–MVO 2 relation after 6 hours. Contractility increased immediately with dobutamine infusion ( dP/ dt max ; 1636 ± 478 vs 2888 ± 818 mmHg/s, P < 0.05) and persisted throughout the protocol (2864 ± 1055 mmHg/s, P < 0.05). Arterial free fatty acid increased gradually (0.22 ± 0.13 vs 0.39 ± 0.30 mM, P < 0.05) with peak levels after 6 hours (1.1 ± 0.4 mM, P < 0.05). By combining dobutamine with L-748,337 the progressive impairment in cardiac efficiency was attenuated. Interestingly, this combined treatment effect occurred despite similar alterations in cardiac inotropy and substrate supply. We conclude that the extent of cardiac inefficiency following adrenergic stimulation is dependent on the duration of drug infusion, and β 3 AR blockade may attenuate this effect.
No takes yet. Share an insight, caveat, or question.
Rødland et al. (2021) studied Dobutamine-induced cardiac inefficiency. L-748,337 + dobutamine vs. Dobutamine alone and saline was evaluated on Cardiac efficiency (MVO2 to left ventricular work relation). Selective β3 adrenergic receptor antagonism with L-748,337 attenuated dobutamine-induced progressive impairment in cardiac efficiency while preserving inotropy in an anesthetized pig model.
Synapse has enriched 10 related papers. Consider them for comparative context: